Catalent is a drug manufacturers - specialty & generic business based in the US. Catalent shares (CTLT) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $59.00 – an increase of 0.15% over the previous week. Catalent employs 17,000 staff and has a trailing 12-month revenue of around $4.4 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $59.00 |
|---|---|
| 52-week range | $36.74 - $61.20 |
| 50-day moving average | $59.89 |
| 200-day moving average | $57.71 |
| Wall St. target price | $63.43 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.27 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $58.88 from 2024-11-19
| 1 week (2024-11-14) | -0.05% |
|---|---|
| 1 month (2024-10-21) | -2.16% |
| 3 months (2024-08-21) | -0.89% |
| 6 months (2024-05-21) | 7.13% |
| 1 year (2023-11-21) | 47.79% |
|---|---|
| 2 years (2022-11-21) | 40.56% |
| 3 years (2021-11-19) | 127.11 |
| 5 years (2019-11-21) | 14.22% |
Valuing Catalent stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalent's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Catalent's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.9477. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Catalent's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Catalent's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $462 million.
The EBITDA is a measure of a Catalent's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $4.4 billion |
|---|---|
| Gross profit TTM | $1 billion |
| Return on assets TTM | -0.18% |
| Return on equity TTM | -11.19% |
| Profit margin | -9.34% |
| Book value | $19.52 |
| Market Capitalization | $10.7 billion |
TTM: trailing 12 months
We're not expecting Catalent to pay a dividend over the next 12 months.
Over the last 12 months, Catalent's shares have ranged in value from as little as $36.7387 up to $61.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Catalent's is 1.158. This would suggest that Catalent's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Catalent, Inc. , together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.